Changes in histaminergic system in neuropsychiatric disorders and the potential treatment consequences

Ling Shan; Dick F Swaab

doi:10.2174/1570159X19666210909144930

Changes in histaminergic system in neuropsychiatric disorders and the potential treatment consequences

Ling Shan, Dick F Swaab

Netherlands Institute for Neuroscience (NIN)

Research output: Contribution to journal/periodical › Article › Scientific › peer-review

8 Citations (Scopus)

168 Downloads (Pure)

Abstract

In contrast to that of other monoamine neurotransmitters, the association of the histaminergic system with neuropsychiatric disorders is not well documented. In the last two decades, several clinical studies involved in the development of drugs targeting the histaminergic system have been reported. These include the H3R-antagonist/inverse agonist, pitolisant, used for the treatment of excessive sleepiness in narcolepsy, and the H1R antagonist, doxepin, used to alleviate symptoms of insomnia. The current review summarizes reports from animal models, including genetic and neuroimaging studies, as well as human brain samples and cerebrospinal fluid measurements from clinical trials, on the possible role of the histaminergic system in neuropsychiatric disorders. These studies will potentially pave the way for novel histamine-related therapeutic strategies.

Original language	English
Pages (from-to)	403-411
Journal	Current neuropharmacology
Volume	20
DOIs	https://doi.org/10.2174/1570159X19666210909144930
Publication status	Published - 2022

Access to Document

10.2174/1570159X19666210909144930

Shan2022Final published version, 6.22 MB

Cite this

@article{5027324f9fd941ee8e0f9514d95df2f5,

title = "Changes in histaminergic system in neuropsychiatric disorders and the potential treatment consequences",

abstract = "In contrast to that of other monoamine neurotransmitters, the association of the histaminergic system with neuropsychiatric disorders is not well documented. In the last two decades, several clinical studies involved in the development of drugs targeting the histaminergic system have been reported. These include the H3R-antagonist/inverse agonist, pitolisant, used for the treatment of excessive sleepiness in narcolepsy, and the H1R antagonist, doxepin, used to alleviate symptoms of insomnia. The current review summarizes reports from animal models, including genetic and neuroimaging studies, as well as human brain samples and cerebrospinal fluid measurements from clinical trials, on the possible role of the histaminergic system in neuropsychiatric disorders. These studies will potentially pave the way for novel histamine-related therapeutic strategies.",

author = "Ling Shan and Swaab, {Dick F}",

note = "Copyright{\textcopyright} Bentham Science Publishers; For any queries, please email at [email protected].",

year = "2022",

doi = "10.2174/1570159X19666210909144930",

language = "English",

volume = "20",

pages = "403--411",

journal = "Current neuropharmacology",

issn = "1570-159X",

publisher = "Bentham Science Publishers",

}

TY - JOUR

T1 - Changes in histaminergic system in neuropsychiatric disorders and the potential treatment consequences

AU - Shan, Ling

AU - Swaab, Dick F

PY - 2022

Y1 - 2022

N2 - In contrast to that of other monoamine neurotransmitters, the association of the histaminergic system with neuropsychiatric disorders is not well documented. In the last two decades, several clinical studies involved in the development of drugs targeting the histaminergic system have been reported. These include the H3R-antagonist/inverse agonist, pitolisant, used for the treatment of excessive sleepiness in narcolepsy, and the H1R antagonist, doxepin, used to alleviate symptoms of insomnia. The current review summarizes reports from animal models, including genetic and neuroimaging studies, as well as human brain samples and cerebrospinal fluid measurements from clinical trials, on the possible role of the histaminergic system in neuropsychiatric disorders. These studies will potentially pave the way for novel histamine-related therapeutic strategies.

AB - In contrast to that of other monoamine neurotransmitters, the association of the histaminergic system with neuropsychiatric disorders is not well documented. In the last two decades, several clinical studies involved in the development of drugs targeting the histaminergic system have been reported. These include the H3R-antagonist/inverse agonist, pitolisant, used for the treatment of excessive sleepiness in narcolepsy, and the H1R antagonist, doxepin, used to alleviate symptoms of insomnia. The current review summarizes reports from animal models, including genetic and neuroimaging studies, as well as human brain samples and cerebrospinal fluid measurements from clinical trials, on the possible role of the histaminergic system in neuropsychiatric disorders. These studies will potentially pave the way for novel histamine-related therapeutic strategies.

U2 - 10.2174/1570159X19666210909144930

DO - 10.2174/1570159X19666210909144930

M3 - Article

C2 - 34521328

SN - 1570-159X

VL - 20

SP - 403

EP - 411

JO - Current neuropharmacology

JF - Current neuropharmacology

ER -

Changes in histaminergic system in neuropsychiatric disorders and the potential treatment consequences

Abstract

Access to Document

Fingerprint

Cite this